BioHarvest Sciences Beheer

Beheer criteriumcontroles 4/4

De CEO BioHarvest Sciences is Ilan Sobel, benoemd in Jun2020, heeft een ambtstermijn van 4.42 jaar. bezit rechtstreeks 1.25% van de aandelen van het bedrijf, ter waarde € 1.28M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 3.8 jaar.

Belangrijke informatie

Ilan Sobel

Algemeen directeur

US$481.6k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.4yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

CEO

Ilan Sobel

4.4yrs

Tenure

US$481,581

Compensatie

Mr. Ilan Sobel has been the Chief Executive Officer at BioHarvest Sciences Inc. since June 9, 2020. He served as Chief Operating Officer at Weissbeerger Ltd. and then Chief Commercial Officer of Weissbeerg...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Zaki Rakib	Co-Founder	6.2yrs	US$1.16m	geen gegevens
Ilan Sobel	Chief Executive Officer	4.4yrs	US$481.58k	1.25% € 1.3m
Yochi Hagay	Co-Founder	6.2yrs	US$67.02k	0.18% € 187.3k
Ilana Belzer	Chief Operating Officer	1.6yrs	US$275.09k	0.0032% € 3.2k
David Ryan	VP of Investor Relations & Secretary	11.6yrs	US$44.45k	0.23% € 230.5k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	2.7yrs	US$421.35k	0.015% € 15.2k
Bar Dichter	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Matthew Zrebiec	Vice President of Business Development	less than a year	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 8MV0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zaki Rakib	Co-Founder	6.2yrs	US$1.16m	geen gegevens
Yochi Hagay	Co-Founder	3.8yrs	US$67.02k	0.18% € 187.3k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	1.8yrs	US$421.35k	0.015% € 15.2k
Steven Lehrer	Member of Board of Advisor	3.1yrs	geen gegevens	geen gegevens
Vincent Giampapa	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dennis Goodman	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
David Tsur	Independent Non-Executive Director	3.1yrs	US$37.36k	geen gegevens
David Brady	Member of Scientific Advisory Board	4.1yrs	geen gegevens	geen gegevens
Scott McCune	Member of Advisory Board	3.7yrs	geen gegevens	geen gegevens
Vivien Rakib	Independent Director	6.2yrs	US$26.65k	17.5% € 17.9m
John Fiddick	Independent Director	5.8yrs	US$26.65k	geen gegevens
Roberto Chait	Member of Advisory Board	4.1yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 8MV0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

BioHarvest Sciences Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

No independent directors

Recent updates

New minor risk - Share price stability

BioHarvest Sciences Inc. to Report Q3, 2024 Results on Nov 14, 2024

Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director

Second quarter 2024 earnings released: US$0.042 loss per share (vs US$0.21 loss in 2Q 2023)

New minor risk - Market cap size

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in funding

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023)

Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022)

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024

BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding

Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.009 loss in 3Q 2022)

Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding

Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022)

BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in funding

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022)

Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021)

BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic Neuritis

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

BioHarvest Sciences Inc. announced that it has received CAD 10.03355 million in funding

Bioharvest Sciences Inc. Provides Revenue Guidance for the Year 2022 and 2023

Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021)

BioHarvest Sciences Inc. Appoints Gavriel Lambert to its Board of Advisors

Bioharvest Sciences Inc. Hires Dr. Brian S. Cornblatt as Chief Medical Officer

First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021)

Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020)

No independent directors

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.3 million in funding

BioHarvest Sciences Inc. Reiterates Sales Orders Guidance for 2022

BioHarvest Sciences Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020)

Bioharvest Sciences Inc. Unveils New Groundbreaking Cannabis Trichome Structure

BioHarvest Sciences Inc. announced that it expects to receive CAD 4 million in funding

BioHarvest Sciences Inc. Reveals Vinia Anti-Aging Capabilities Via Blood Flow Improvement

First quarter 2021 earnings released

Full year 2020 earnings released

Bioharvest Sciences Inc. Unveils Unique Polyphenolic Content of Its Upcoming Olive Based Nutraceutical

Bioharvest Sciences Inc. Announces Partnership with Boldt and Summit Strategy Group to Develop A Sustainability Framework and Esg Report

BioHarvest Sciences Inc. Announces a Major Breakthrough in the Growth of Cannabis TRICHOMES across Multiple Strains in Liquid Media

BioHarvest Sciences Inc. announced that it has received CAD 6.179932 million in funding

BioHarvest Sciences Inc. announced that it expects to receive CAD 6 million in funding

BioHarvest Sciences Inc. Appoints Dennis Goodman to Its Scientific Advisory Board

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd